1-Jahres-Chart (nicht börsennotiert)
Chart-Typ:
Zeitraum:
| Form 8.3 - The Vanguard Group, Inc.: BHP Group Limited | DJ Form 8.3 - The Vanguard Group, Inc.: BHP Group Limited
The Vanguard Group, Inc. ( )
Form 8.3 - The Vanguard Group, Inc.: BHP Group Limited
03-May-2024 / 14:24 GMT/BST
=----------------------------------------------------------------------------------------------------------------------... ► Artikel lesen |
| Norges Bank - Form 8.3 - BHP Group Limited | Norges Bank - Form 8.3 - BHP Group Limited
PR Newswire
LONDON, United Kingdom, May 03
Amendment of the disclosure submitted on 03/05/2024 FORM 8.3PUBLIC OPENING POSITION... ► Artikel lesen |
| Norges Bank - Form 8.3 - BHP Group Limited | Norges Bank - Form 8.3 - BHP Group Limited
PR Newswire
LONDON, United Kingdom, May 03
FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH... ► Artikel lesen |
| XFRA 433: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
| Innodata Inc.: Innodata Withdraws Proposal to Acquire Appen | NEW YORK, NY / ACCESSWIRE / March 13, 2024 / INNODATA INC. (NASDAQ:INOD) Innodata announced today that it has withdrawn a previously submitted confidential, non-binding, indicative proposal (the "Proposal")... ► Artikel lesen |
| XFRA 433: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAPPEN LTD 433 AU000000APX3... ► Artikel lesen |
| CSL: Real-World Evidence Study Proves Effectiveness Of Cell-Based Quadrivalent Influenza Vaccines | CANBERA (dpa-AFX) - CSL Seqirus, a subsidiary of CSL Ltd. (CSL.AX), Thursday said that a real-world evidence study shows that a cell-based quadrivalent influenza vaccine has been more effective... ► Artikel lesen |
| ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen |
| Vifor International AG (CSL Vifor): CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI (sparsentan) for the treatment of IgA Nephropathy | First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
